P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)B.C. Cho, D.-W. Kim, J. Xie et al.|Journal of Thoracic Oncology|2022Cited by 7
MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLCM.E. Marmarelis, B.C. Cho, S.-H. Lee et al.|Journal of Thoracic Oncology|2022Cited by 4
MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2S.-H. Lee, M.E. Marmarelis, Byoung Chul Cho et al.|Journal of Thoracic Oncology|2023Cited by 4
EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 PolydamasP.J. Voon, B.C. Cho, Ju Le Tan et al.|Journal of Thoracic Oncology|2024Cited by 1